Terms ending in 2039
Every in-force patent on Codexis, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,015,180 | Carboxyesterase Polypeptides for Amide Coupling In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 10,889,806 | Engineered Pantothenate Kinase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,034,948 | Engineered Phosphopentomutase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,162,105 | Engineered Purine Nucleoside Phosphorylase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,274,286 | Engineered Deoxyribose-Phosphate Aldolases In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,466,259 | Engineered Galactose Oxidase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 11,845,968 | Engineered Deoxyribose-Phosphate Aldolases In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,012,618 | Engineered Galactose Oxidase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,110,513 | Engineered Pantothenate Kinase Variant Enzymes In force · High confidence | Codexis, Inc. | In force | High confidence | |
| US 12,460,195 | Engineered Deoxyribose-Phosphate Aldolases In force · High confidence | Codexis, Inc. | In force | High confidence | |
| 7 more term ends in 2039 · Pro | |||||
10 of 17 patents shown. Soonest term end first, then patent number.
Pro members see all 17.
16 of these are in force and held by Codexis, Inc..
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.